FIGURE 5 from An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers

An increased ENI10 score predicts patient's survival in several cancer types. A, ssGSEA ENI10 score in pairs of normal and tumor samples from TCGA's Pan-Cancer atlas linked by gray lines and the difference are color coded on the dots representing the tumor samples. ACC: adrenocortical carcinoma, BLCA: bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL: cholangiocarcinoma, COAD: colon adenocarcinoma, DLBC: lymphoid neoplasm diffuse large B-cell lymphoma, ESCA: esophageal carcinoma, HNSC: head and neck squamous cell carcinoma, KICH: kidney chromophobe, KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell carcinoma, LAML: acute myeloid leukemia, LGG: low-grade glioma, LIHC: liver hepatocellular carcinoma, LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma, MESO: mesothelioma, OV: ovarian cancer, PCPG: pheochromocytoma and paraganglioma, PRAD: prostate adenocarcinoma, READ: rectum adenocarcinoma, SARC: sarcoma, SKCM: skin cutaneous melanoma, STAD: stomach adenocarcinoma, TGCT: testicular germ cell tumor, THCA: thyroid carcinoma, THYM: thymoma, UCEC: uterine corpus endometrial carcinoma, UCS: uterine carcinosarcoma, UVM: uveal melanoma. B, Correlation of the ENI10 score and survival outcome for each type of cancer of TCGA Pan-Cancer atlas estimated by HRs of PFS corresponding to one SD of the score taken as a continuous variable. Dots show the HR and adjacent bars the 95% confidence interval. C, Examples of PFS curves from TCGA Pan-Cancer atlas in the whole cohort and as a function of stage estimated using the Kaplan–Meier method and compared with the log-rank test between groups of patients defined by the median of the ENI10 score (low scores in blue and high scores in red). D, ssGSEA ENI10 score in transcriptomic data from nevus or melanoma at different stage of clinically defined transformation. E, Using transcriptomic data from the “Genomics of drug sensitivity in cancer” project from the Sanger Institute, ENI10 score of all human cancers cell lines available were correlated with their IC₅₀ to 441 drugs. Targets of the drugs with a significative negative correlation between the ENI10 ssGSEA score and IC₅₀ (indicating a sensitivity to the drug when the ENI10 score increase) are shown. According to the GDSC guidelines, red dots show drugs with a significative IC₅₀ correlation with the ENI10 score with a P value inferior to 0.001 and a Benjamini–Hochberg FDR inferior to 0.25. Black dots show suggestive correlations with a P value inferior to 0.005 and a nonparametric P value inferior to 0.1.